Natural killer cell immunotherapy against multiple myeloma: Progress and possibilities

被引：12

作者：

Liu, Pan ^{[1
]}

Jin, Yanxia ^{[1
]}

Sattar, Haseeb ^{[2
]}

Liu, Hailing ^{[3
]}

Xie, Weiling ^{[1
]}

Zhou, Fuling ^{[1
,4
]}

机构：

[1] Wuhan Univ, Dept Hematol, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China

[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Affiliated Hosp, Dept Clin Pharm,Wuhan Union Hosp, Wuhan, Hubei, Peoples R China

[3] Xi An Jiao Tong Univ, Dept Clin Hematol, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China

[4] Hubei Key Lab Tumor Biol Behav, Wuhan, Hubei, Peoples R China

来源：

JOURNAL OF LEUKOCYTE BIOLOGY | 2018年 / 103卷 / 05期

基金：

中国国家自然科学基金;

关键词：

immunotherapy; multiple myeloma; natural killer cell; HLA CLASS-I; NK CELLS; MEDIATED LYSIS; MONOCLONAL-ANTIBODIES; CANCER-IMMUNOTHERAPY; BISPECIFIC ANTIBODY; THERAPEUTIC TARGET; ADOPTIVE TRANSFER; T-CELLS; ACTIVATION;

D O I：

10.1002/JLB.2RU0517-176RR

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Multiple myeloma (MM) is a complex aggressive mature B-cell malignancy. Although with the wide application of chemotherapy drugs, it remains incurable and the vast majority of patients relapse. Natural killer (NK) cells, also known as CD56(+)CD3(-) large granular lymphocytes, are cytotoxic innate immune cells against MM without prior sensitization steps. NK cell-based immunotherapy is extensively promising in a wide range of clinical settings. It is worthy of note that some novel drugs such as monoclonal antibodies (mAbs), proteasome inhibitors (PIs), and immunomodulators (IMiDs) directly or indirectly activate NK cells to enhance their antitumor activity, and the combined regimens significantly improve the prognosis of MM patients. In this review, we summarize recent findings that support a role for NK cells in the pathogenesis of MM and outline innovative approaches in the implementation of NK cell-based immunotherapy against MM. Review on NK cell dysfunction in patients with multiple myeloma.

引用

页码：821 / 828

页数：8

共 95 条

[11] DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells [J].

Carlsten, Mattias ;

Bjorkstrom, Niklas K. ;

Norell, Hakan ;

Bryceson, Yenan ;

van Hall, Thorbald ;

Baumann, Bettina C. ;

Hanson, Mikael ;

Schedvins, Kjell ;

Kiessling, Rolf ;

Ljunggren, Hans-Gustaf ;

Malmberg, Karl Johan .

CANCER RESEARCH, 2007, 67 (03) :1317-1325

[12] CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma [J].

Chu, J. ;

Deng, Y. ;

Benson, D. M. ;

He, S. ;

Hughes, T. ;

Zhang, J. ;

Peng, Y. ;

Mao, H. ;

Yi, L. ;

Ghoshal, K. ;

He, X. ;

Devine, S. M. ;

Zhang, X. ;

Caligiuri, M. A. ;

Hofmeister, C. C. ;

Yu, J. .

LEUKEMIA, 2014, 28 (04) :917-927

[13] The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential [J].

Clemenceau, Beatrice ;

Vivien, Regine ;

Pellat, Catherine ;

Foss, Michael ;

Thibault, Gilles ;

Vie, Henri .

MABS, 2013, 5 (04) :587-594

[14] Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC [J].

Collins, Shauna M. ;

Bakan, Courtney E. ;

Swartzel, Gina D. ;

Hofmeister, Craig C. ;

Efebera, Yvonne A. ;

Kwon, Hakju ;

Starling, Gary C. ;

Ciarlariello, David ;

Bhaskar, Shakthi ;

Briercheck, Edward L. ;

Hughes, Tiffany ;

Yu, Jianhua ;

Rice, Audie ;

Benson, Don M., Jr. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (12) :1841-1849

[15] Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function [J].

Cruz-Munoz, Mario-Ernesto ;

Dong, Zhongjun ;

Shi, Xiaochu ;

Zhang, Shaohua ;

Veillette, Andre .

NATURE IMMUNOLOGY, 2009, 10 (03) :297-305

[16] Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [J].

Davies, FE ;

Raje, N ;

Hideshima, T ;

Lentzsch, S ;

Young, G ;

Tai, YT ;

Lin, B ;

Podar, K ;

Gupta, D ;

Chauhan, D ;

Treon, SP ;

Richardson, PG ;

Schlossman, RL ;

Morgan, GJ ;

Muller, GW ;

Stirling, DI ;

Anderson, KC .

BLOOD, 2001, 98 (01) :210-216

[17] Immunomodulatory drugs as a therapy for multiple myeloma [J].

De Raeve, H. ;

Vanderkerken, K. .

CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2006, 7 (06) :415-421

[18] Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors [J].

Delahaye, Nicolas F. ;

Rusakiewicz, Sylvie ;

Martins, Isabelle ;

Menard, Cedric ;

Roux, Stephan ;

Lyonnet, Luc ;

Paul, Pascale ;

Sarabi, Matthieu ;

Chaput, Nathalie ;

Semeraro, Michaela ;

Minard-Colin, Veronique ;

Poirier-Colame, Vichnou ;

Chaba, Kariman ;

Flament, Caroline ;

Baud, Veronique ;

Authier, Helene ;

Kerdine-Roemer, Saadia ;

Pallardy, Marc ;

Cremer, Isabelle ;

Peaudecerf, Laetitia ;

Rocha, Benedita ;

Valteau-Couanet, Dominique ;

Gutierrez, Javier Celis ;

Nunes, Jacques A. ;

Commo, Frederic ;

Bonvalot, Sylvie ;

Ibrahim, Nicolas ;

Terrier, Philippe ;

Opolon, Paule ;

Bottino, Cristina ;

Moretta, Alessandro ;

Tavernier, Jan ;

Rihet, Pascal ;

Coindre, Jean-Michel ;

Blay, Jean-Yves ;

Isambert, Nicolas ;

Emile, Jean-Francois ;

Vivier, Eric ;

Lecesne, Axel ;

Kroemer, Guido ;

Zitvogel, Laurence .

NATURE MEDICINE, 2011, 17 (06) :700-+

[19] Immune Therapy for Cancer [J].

Dougan, Michael ;

Dranoff, Glenn .

ANNUAL REVIEW OF IMMUNOLOGY, 2009, 27 :83-117

[20] Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective [J].

Eguizabal, Cristina ;

Zenarruzabeitia, Olatz ;

Monge, Jorge ;

Santos, Silvia ;

Angel Vesga, Miguel ;

Maruri, Natalia ;

Arrieta, Arantza ;

Rinon, Marta ;

Tamayo-Orbegozo, Estibaliz ;

Amo, Laura ;

Larrucea, Susana ;

Borrego, Francisco .

FRONTIERS IN IMMUNOLOGY, 2015, 5

← 1 2 3 4 5 6 7 8 9 10 →